Dysphagia in head and neck cancer patients following intensity modulated radiotherapy (IMRT)

BackgroundTo evaluate the objective and subjective long term swallowing function, and to relate dysphagia to the radiation dose delivered to the critical anatomical structures in head and neck cancer patients treated with intensity modulated radiation therapy (IMRT, +/- chemotherapy), using a midline protection contour (below hyoid, ~level of vertebra 2/3).Methods82 patients with stage III/IV squamous cell carcinoma of the larynx, oropharynx, or hypopharynx, who underwent successful definitive (n = 63, mean dose 68.9Gy) or postoperative (n = 19, mean dose 64.2Gy) simultaneous integrated boost (SIB) -IMRT either alone or in combination with chemotherapy (85%) with curative intent between January 2002 and November 2005, were evaluated retrospectively. 13/63 definitively irradiated patients (21%) presented with a total gross tumor volume (tGTV) >70cc (82-173cc; mean 106cc). In all patients, a laryngo-pharyngeal midline sparing contour outside of the PTV was drawn. Dysphagia was graded according subjective patient-reported and objective observer-assessed instruments. All patients were re-assessed 12 months later. Dose distribution to the swallowing structures was calculated.ResultsAt the re-assessment, 32-month mean post treatment follow-up (range 16-60), grade 3/4 objective toxicity was assessed in 10%. At the 32-month evaluation as well as at the last follow up assessment mean 50 months (16-85) post-treatment, persisting swallowing dysfunction grade 3 was subjectively and objectively observed in 1 patient (1%). The 5-year local control rate of the cohort was 75%; no medial marginal failures were observed.ConclusionsOur results show that sparing the swallowing structures by IMRT seems effective and relatively safe in terms of avoidance of persistent grade 3/4 late dysphagia and local disease control.

[1]  Jimmy J Caudell,et al.  Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck. , 2010, International journal of radiation oncology, biology, physics.

[2]  G. Studer,et al.  Surviving hypopharynx-larynx carcinoma in the era of IMRT. , 2010, International journal of radiation oncology, biology, physics.

[3]  Tai-Lin Huang,et al.  Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy-a longitudinal study. , 2008, International journal of radiation oncology, biology, physics.

[4]  K. Rufibach,et al.  Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Spencer,et al.  Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer. , 2009, International journal of radiation oncology, biology, physics.

[6]  K. Chao,et al.  Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine. , 2003, Seminars in oncology.

[7]  P. Dirix,et al.  Value of intensity-modulated radiotherapy in Stage IV head-and-neck squamous cell carcinoma. , 2010, International journal of radiation oncology, biology, physics.

[8]  Fabrice Denis,et al.  Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. , 2003, International journal of radiation oncology, biology, physics.

[9]  H. Thierens,et al.  Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. , 2009, International journal of radiation oncology, biology, physics.

[10]  D. Rietveld,et al.  A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  R. Weber,et al.  Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. , 2003, The New England journal of medicine.

[12]  K. Vineberg,et al.  Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? , 2004, International journal of radiation oncology, biology, physics.

[13]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.

[14]  Suzanne L Wolden,et al.  A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. , 2006, International journal of radiation oncology, biology, physics.

[15]  F. Feng,et al.  Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. , 2007, International journal of radiation oncology, biology, physics.

[16]  A. Garden,et al.  A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. , 2000, International journal of radiation oncology, biology, physics.

[17]  K. Harrington,et al.  Dysphagia in head and neck cancer. , 2009, Cancer treatment reviews.

[18]  Laurence E Court,et al.  Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[19]  G. Studer,et al.  IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients , 2006, Radiation oncology.

[20]  M. Sormani,et al.  Dosimetric predictors of laryngeal edema. , 2007, International journal of radiation oncology, biology, physics.

[21]  Peter C Levendag,et al.  Treatment techniques and site considerations regarding dysphagia-related quality of life in cancer of the oropharynx and nasopharynx. , 2008, International journal of radiation oncology, biology, physics.

[22]  Margie Hunt,et al.  Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. , 2006, International journal of radiation oncology, biology, physics.

[23]  F. Feng,et al.  Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: Clinical and functional results , 2011 .

[24]  L. Dawson,et al.  Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. , 2002, International journal of radiation oncology, biology, physics.

[25]  P. Levendag,et al.  Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  L. Peters,et al.  Intensity-modulated radiotherapy for nasopharyngeal carcinoma: clinical correlation of dose to the pharyngo-esophageal axis and dysphagia. , 2007, International journal of radiation oncology, biology, physics.